KAYLEEN WILSON: Open Payments
NPI 1790088797 · ROY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 45 payments from 19 companies in 2025. Trend: 2023 $546 · 2024 $966 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $90 |
| PFIZER INC. | 3 | $60 |
| Astellas Pharma US Inc | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Dynavax Technologies Corporation | 2 | $27 |
| Abbott Laboratories | 1 | $23 |
Products named: TRELEGY ELLIPTA, CAPLYTA, Veozah, Auvelity, NURTEC ODT, MOUNJARO, SPRAVATO, XIFAXAN.
Industry payments across UT — which companies pay providers there.
